KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Other Accumulated Expenses: 2010-2020

Historic Other Accumulated Expenses for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Dec 2020 value amounting to $122.4 million.

  • Regeneron Pharmaceuticals' Other Accumulated Expenses rose 44.00% to $122.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was $122.4 million, marking a year-over-year increase of 44.00%. This contributed to the annual value of $122.4 million for FY2020, which is 44.00% up from last year.
  • Latest data reveals that Regeneron Pharmaceuticals reported Other Accumulated Expenses of $122.4 million as of Q4 2020, which was up 26.32% from $96.9 million recorded in Q3 2020.
  • In the past 5 years, Regeneron Pharmaceuticals' Other Accumulated Expenses registered a high of $122.4 million during Q4 2020, and its lowest value of $267,000 during Q4 2017.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $96.9 million (2020), whereas its average is $98.6 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 518.22% in 2016, then tumbled by 93.51% in 2017.
  • Over the past 4 years, Regeneron Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $1.2 million in 2016, then slumped by 77.33% to $267,000 in 2017, then reached $85.0 million in 2019, then spiked by 44.00% to $122.4 million in 2020.
  • Its Other Accumulated Expenses stands at $122.4 million for Q4 2020, versus $96.9 million for Q3 2020 and $103.8 million for Q2 2020.